Answers are grounded in this paper and cite their sources.
Clarifies the ESC guideline recommendation regarding the addition of ARBs in symptomatic chronic heart failure patients already on ACE inhibitors.
Dr Krum suggests changes to the ESC Guidelines on the diagnosis and treatment of chronic heart failure and of Figure 4 in particular. We appreciate the opportunity to clarify the role of the figure. As stated in the legend, the figure should be viewed as an example for decision-making. The figure is designed to complement the explanatory text, but is no substitute for it. In the text and in Table 18, it is stated (as pointed out by Krum) that the addition of an angiotensin receptor blocker (ARB) should be considered in symptomatic patients regardless of background angiotensin-converting enzyme (ACE)-inhibitor therapy. The reason for not stating that ACE-inhibitor/ARB should be used in combination in the figure is that these patients require re-evaluation after the institution of basic therapy and only those with persisting NYHA class-II symptoms should, in the absence of an indication for an ARA, then receive an ARB.
No takes yet. Share an insight, caveat, or question.
Swedberg et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: